BETHESDA, Md., Feb. 4 /PRNewswire-FirstCall/ -- Micromet, Inc. (NASDAQ: MITI) today announced that it will host a Research & Development Day for the investment community on Wednesday, February 10, 2010 from 8:00 AM - 11:00 AM ET at the Yale Club in New York City. Members of the Company's leadership team will outline near-term development plans for the Company's lead product candidate blinatumomab (MT103) and will provide an update on the Company's earlier stage BiTE® antibodies. Interested parties may access a live audio webcast of the presentation via the homepage of the Micromet website, http://www.micromet-inc.com/ or by dialing 866-700-7477 (U.S.) or 617-213-8840 (International), passcode: 23649136. About Micromet, Inc. Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® technology, as well as conventional monoclonal antibodies. Two of Micromet's BiTE antibodies and three of its conventional antibodies are currently in clinical trials. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including sanofi-aventis, Bayer Schering Pharma, Merck Serono, MedImmune and Nycomed. Additional information can be found at http://www.micromet-inc.com/. DATASOURCE: Micromet, Inc. CONTACT: Jennifer Neiman, Director, Corporate Communications, Micromet, Inc., +1-240-235-0246, Web Site: http://www.micromet-inc.com/

Copyright